Ruxolitinib | INCB18424;INCB 018424 | 鲁索替尼 | JAK

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

产品名称	JAK1 ↓ ↑	JAK2 ↓ ↑	JAK3 ↓ ↑	Tyk2 ↓ ↑	其他靶点	纯度
Decernotinib	+++ JAK1, Ki: 11 nM JAK1, IC50: 11 nM	+++ JAK2, Ki: 13 nM	++++ JAK3, Ki: 2.5 nM	+++ TYK2, Ki: 13 nM		99%+
ZM39923 HCl	+ JAK1, pIC50: 4.4		+ JAK3, pIC50: 7.1		EGFR	97%
Cerdulatinib	+++ JAK1, IC50: 12 nM	+++ JAK2, IC50: 6 nM	+++ JAK3, IC50: 8 nM	++++ TYK2, IC50: 0.5 nM		99%+
Momelotinib	+++ JAK1, IC50: 11 nM	++ JAK2, IC50: 18 nM	+ JAK3, IC50: 155 nM			99%+
XL019	+ JAK1, IC50: 134.3 nM	++++ JAK2, IC50: 2.2 nM	+ JAK3, IC50: 214.2 nM		FLT3	99%+
Ruxolitinib	+++ JAK1, IC50: 3.3 nM	++++ JAK2, IC50: 2.8 nM				98%
Tofacitinib	+ JAK1, IC50: 112 nM	++ JAK2, IC50: 20 nM	++++ JAK3, IC50: 1 nM			98%
Ruxolitinib (S enantiomer)	+++ JAK1, IC50: 3.3 nM	++++ JAK2, IC50: 2.8 nM		++ TYK2, IC50: 19 nM		98%
Filgotinib	+++ JAK1, IC50: 10 nM	++ JAK2, IC50: 28 nM	+ JAK3, IC50: 810 nM	+ TYK2, IC50: 116 nM		99%
Baricitinib	+++ JAK1, IC50: 5.9 nM	+++ JAK2, IC50: 5.7 nM		++ TYK2, IC50: 53 nM		99%
Gandotinib	++ JAK1, IC50: 19.8 nM	++++ JAK2, IC50: 0.288 nM JAK2 (V617F), Ki: 0.245 nM	++ JAK3, IC50: 48.0 nM	++ TYK2, IC50: 44 nM	FLT3	99%+
Oclacitinib maleate	+++ JAK1, IC50: 10nM	++ JAK2, IC50: 18nM	+ JAK3, IC50: 99nM	+ TYK2, IC50: 84nM		98+%
NVP-BSK805 2HCl	++ JAK1, IC50: 31.63 nM	++++ JAK2, IC50: ~0.5 nM	++ JAK3, IC50: 18.68 nM	+++ TYK2, IC50: 10.76 nM		99+%
Peficitinib		✔				98%
Go6976		✔			FLT3	99%+
AZD-1480		++++ JAK2, IC50: 0.26 nM				99%+
Fedratinib		+++ JAK2, IC50: 3 nM JAK2 (V617F), IC50: 3 nM			RET,FLT3	99%+
WP1066		+ JAK2, IC50: 2.3 μM				98%
Curcumol		✔				98%
AZ960		++++ JAK2, Ki: 0.45 nM JAK2, IC50: <3 nM				97%
GLPG0634 analog		✔				99%+
CEP-33779		++++ JAK2, IC50: 1.8 nM				99%+
FLLL32		+ JAK2, IC50: <5 μM				99%+
WHI-P154			+ JAK3, IC50: 1.8 μM		VEGFR,EGFR,Src	98%
BMS-911543		++++ JAK2, IC50: 1.1 nM	+ JAK3, IC50: 75 nM	++ TYK2, IC50: 66 nM		98%
TG101209		+++ JAK2, IC50: 6 nM	+ JAK3, IC50: 169 nM		RET,FLT3	99%+
AT9283		++++ JAK2, IC50: 1.2 nM	++++ JAK3, IC50: 1.1 nM			99%+
Pacritinib		++ JAK2, IC50: 23 nM JAK2 (V617F), IC50: 19 nM	+ JAK3, IC50: 520 nM	++ TYK2, IC50: 50 nM	FLT3	97%
Tofacitinib citrate		++ JAK2, IC50: 20 nM	++++ JAK3, IC50: 1 nM			99%
FM-381			++++ JAK3, IC50: 127 pM			98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

细胞系	浓度	检测类型	检测时间	活动说明	数据源
A549		Growth Inhibition Assay		IC50=0.04 μM	25213670
A549/DDP		Growth Inhibition Assay		IC50=0.22 μM	25213670
A549/DDP	30 nM	Function Assay	48 h	Down-regulation of STAT3 phosphorylation	25213670
A549/DDP	30 nM	Apoptosis Assay	48 h	Induction of apoptosis	25213670

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT03274778	Prostate Cancer	Not Applicable	Recruiting	May 1, 2019	Switzerland ... 展开 >> Istituto Oncologico della Svizzera Italiana (IOSI) Recruiting Bellinzona, Switzerland, 6500 Contact: Ricardo Pereira Mestre, Dr. med. +41 (0)91 811 84 46 Ricardo.PereiraMestre@eoc.ch Contact: Barbara Marongiu +41 (0)91 811 91 20 barbara.marongiu@eoc.ch 收起 <<
NCT02120417	-		Terminated(The study was termi... 展开 >>nated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation.) 收起 <<	-	-
NCT01914484	Chronic Phase Chronic Myeloid ... 展开 >>Leukemia Accelerated Phase Chronic Myeloid Leukemia Blastic Phase Chronic Myeloid Leukemia Philadelphia Positive Acute Lymphoblastic Leukemia Resistant to Tyrosine Kinase Inhibitor Therapy 收起 <<	Phase 1 Phase 2	Unknown	July 2016	Canada, Ontario ... 展开 >> Princess Margaret Hospital / University Health Network Recruiting Toronto, Ontario, Canada, M5G 2M9 Contact: Sima Bogomilsky, RN BScN CON(C) 416-946-4646 sima.bogomilsky@uhn.on.ca Contact: Sonal Malhotra, M.Sc., Ph.D,CCRP 416-946-4501 ext 3449 sonal.malhotra@uhn.ca Principal Investigator: Dennis Kim, MD/PhD Sub-Investigator: Jeffrey H Lipton, MD/PhD 收起 <<
NCT02119650	-		Terminated(The study was termi... 展开 >>nated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation.) 收起 <<	-	-
NCT03257644	Atopic Dermatitis	Phase 1	Suspended(Study is currently o... 展开 >>n hold pending amendment update.) 收起 <<	December 2019	United States, California ... 展开 >> Children's Hospital of Los Angeles Los Angeles, California, United States, 90027 Rady Children's Hospital - San Diego San Diego, California, United States, 92123 United States, Colorado National Jewish Health Denver, Colorado, United States, 80206 United States, Illinois Northwestern University Department of Dermatology Chicago, Illinois, United States, 60611 United States, Michigan David Fivenson, MD, Dermatology, PLC Ann Arbor, Michigan, United States, 48103 United States, North Carolina Wake Research Associates Raleigh, North Carolina, United States, 27612 United States, Pennsylvania Penn State Hershey Medical Center Hershey, Pennsylvania, United States, 17033 United States, Texas Texas Dermatology and Laser Specialist Clinical Research San Antonio, Texas, United States, 78218 收起 <<
NCT03654768	Chronic Phase Chronic Myelogen... 展开 >>ous Leukemia, BCR-ABL1 Positive 收起 <<	Phase 2	Recruiting	January 1, 2026	United States, Oregon ... 展开 >> SWOG Recruiting Portland, Oregon, United States, 97239 Contact: Kendra L. Sweet 813-745-6841 kendra.sweet@moffitt.org Principal Investigator: Kendra L. Sweet 收起 <<
NCT02593760	Myelofibrosis	Phase 1	Completed	-	United States, Florida ... 展开 >> Florida Cancer Specialists-Broadway, Fort Myers Fort Myers, Florida, United States, 33908 Florida Cancer Specialist, North Region Saint Petersburg, Florida, United States, 33705 Florida Cancer Specialists West Palm Beach, Florida, United States, 33401 United States, Ohio Oncology Hematology Care Inc Cincinnati, Ohio, United States, 45242 United States, Tennessee Sarah Cannon Research Institute Nashville, Tennessee, United States, 37203 United States, Texas Uni of Texas - Md Anderson Cancer Center; Dept of Leukemia Houston, Texas, United States, 77030 Canada, Alberta Tom Baker Cancer Centre-Calgary; Clinical Research Unit Calgary, Alberta, Canada, T2N 4N2 Canada, Nova Scotia Queen Elizabeth II Health Sciences Centre; Oncology Halifax, Nova Scotia, Canada, B3H 2Y9 Canada, Quebec Centre Hospitalier De L'Universite De Montreal, Hopital Notre-Dame Montreal, Quebec, Canada, H2L 4M1 Germany Uniklinik RWTH Aachen; Med. Klinik IV; Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammz Aachen, Germany, 52074 Campus Virchow-Klinikum Charité Centrum 14; Medizinische Klinik m.S. Hämatologie u. Onkologie Berlin, Germany, 13353 Italy A.O.U. Citta' Della Salute E Della Scienza-P.O. Molinette;S.C. Ematologia Torino, Piemonte, Italy, 10126 Az. Osp. Di Careggi; Divisione Di Ematologia Firenze, Toscana, Italy, 50135 收起 <<
NCT01433445	Idiopathic Myelofibrosis ... 展开 >> Post Essential Thrombocythemia Myelofibrosis Post Polycythemia-Vera Myelofibrosis 收起 <<	Phase 1	Active, not recruiting	December 31, 2018	France ... 展开 >> Novartis Investigative Site Paris, France, 75010 Novartis Investigative Site Villejuif Cedex, France, 94805 Germany Novartis Investigative Site Magdeburg, Germany, 39120 Novartis Investigative Site Mainz, Germany, 55131 Ireland Novartis Investigative Site Dublin, Ireland, DUBLIN 8 Novartis Investigative Site Galway, Ireland Italy Novartis Investigative Site Firenze, FI, Italy, 50134 Novartis Investigative Site Reggio Calabria, RC, Italy, 89124 Novartis Investigative Site Varese, VA, Italy, 21100 United Kingdom Novartis Investigative Site London, United Kingdom, SE1 9RT 收起 <<
NCT02494882	Acute Lymphoblastic Leukemia	Phase 1	Active, not recruiting	June 2019	United States, New York ... 展开 >> Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT01712659	T Cell Leukemia, Adult ... 展开 >> Leukemia, Adult T-Cell T Cell Leukemia, HTLV I Associated 收起 <<	Phase 2	Recruiting	November 1, 2021	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office 888-624-1937 收起 <<
NCT03558607	Secondary Acute Myelogenous Le... 展开 >>ukemia Evolving From Myeloproliferative Disorder 收起 <<	Phase 1 Phase 2	Recruiting	December 31, 2021	Korea, Republic of ... 展开 >> Seoul National University Bundang Hospital Recruiting Seongnam, Korea, Republic of, 13620 Contact: Ryul Kim, Dr +82 10 9412 6108 chrono0707@icloud.com Seoul National University Hospital Recruiting Seoul, Korea, Republic of, 03080 Contact: Ryul Kim, MD +82 10 9412 6108 chrono0707@icloud.com Principal Investigator: Youngil Koh, MD Sub-Investigator: Sung soo Yoon, MD, PhD Sub-Investigator: In ho Kim, MD Sub-Investigator: Ryul Kim, MD 收起 <<
NCT00952289	MPN (Myeloproliferative Neopla... 展开 >>sms) 收起 <<	Phase 3	Completed	-	-
NCT02092324	Atypical Chronic Myeloid Leuke... 展开 >>mia, BCR-ABL1 Negative Chronic Neutrophilic Leukemia 收起 <<	Phase 2	Recruiting	-	United States, California ... 展开 >> Stanford Cancer Institute Palo Alto Recruiting Palo Alto, California, United States, 94304 Contact: Jason Gotlib 650-736-1253 gotlib@stanford.org Principal Investigator: Jason Gotlib United States, Georgia Emory University Hospital/Winship Cancer Institute Recruiting Atlanta, Georgia, United States, 30322 Contact: Elliott F. Winton 404-778-4755 ewinton@emory.edu Principal Investigator: Elliott F. Winton United States, Missouri Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: Stephen Oh 314-362-8846 stoh@dom.wustl.edu Principal Investigator: Stephen Oh United States, Oregon OHSU Knight Cancer Institute Recruiting Portland, Oregon, United States, 97239 Contact: Kim-Hien Dao 503-494-7894 daok@ohsu.edu Principal Investigator: Kim-Hien Dao United States, Texas UT Southwestern/Simmons Cancer Center-Dallas Recruiting Dallas, Texas, United States, 75390 Contact: Robert H. Collins 214-648-4155 robert.collins@utsouthwestern.edu Principal Investigator: Robert H. Collins M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Jorge E. Cortes 713-794-5783 jcortes@mdanderson.org Principal Investigator: Jorge E. Cortes United States, Utah Huntsman Cancer Institute/University of Utah Recruiting Salt Lake City, Utah, United States, 84112 Contact: Michael W. Deininger 801-213-5684 michael.deininger@hci.utah.edu Principal Investigator: Michael W. Deininger 收起 <<
NCT00952289	-		Completed	-	-
NCT01730755	-		-	-	United States, Missouri ... 展开 >> Washington University School of Medicine Saint Louis, Missouri, United States, 63110 收起 <<
NCT02420717	Leukemia	Phase 2	Recruiting	July 2023	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 收起 <<
NCT02119663	-		Terminated(The safety committe... 展开 >>e found no safety issues but recommended halting the study based on a lack of efficacy in a similar trial. The sponsor terminated the trial.) 收起 <<	-	-
NCT02119650	NSCLC (Non-small Cell Lung Car... 展开 >>cinoma) 收起 <<	Phase 2	Terminated(The study was termi... 展开 >>nated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation.) 收起 <<	-	-
NCT03774082	Graft vs Host Disease	Phase 2	Not yet recruiting	June 13, 2025	-
NCT02117479	Pancreatic Cancer	Phase 3	Terminated(The study was termi... 展开 >>nated early based on the results of the planned interim analysis.) 收起 <<	-	-
NCT02974647	Lymphoma	Phase 2	Recruiting	November 2019	United States, Florida ... 展开 >> University of Miami Recruiting Miami, Florida, United States Contact: Jonathan Schatz, MD 305-689-5511 United States, Massachusetts Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02115 Contact: Eric Jacobsen, MD 617-582-9086 United States, New Jersey Memorial Sloan Kettering Basking Ridge Recruiting Basking Ridge, New Jersey, United States, 07920 Contact: Alison Moskowitz, MD 212-639-4839 United States, New York Memorial Sloan Kettering Commack Recruiting Commack, New York, United States, 11725 Contact: Alison Moskowitz, MD 212-639-4839 Memorial Sloan Kettering Westchester Recruiting Harrison, New York, United States, 10604 Contact: Alison Moskowitz, MD 212-639-4839 Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Alison Moskowitz, MD 212-639-4839 Contact: Steven Horwitz, MD 212-639-3045 Principal Investigator: Allison Moskowitz, MD Weill Cornell Medical Center Recruiting New York, New York, United States Contact: Jia Ruan, MD 646-962-2064 Principal Investigator: Jia Ruan, MD 收起 <<
NCT02117479	-		Terminated(The study was termi... 展开 >>nated early based on the results of the planned interim analysis.) 收起 <<	-	-
NCT03333187	Bone Marrow Fibrosis	Phase 2	Recruiting	March 20, 2023	Germany ... 展开 >> Universitätsklinkum Aachen Recruiting Aachen, Germany, 52074 Contact: Edgar Jost, PD Dr. ejost@ukaachen.de Principal Investigator: Edgar Jost, PD Dr. Sub-Investigator: Martina Crysandt, Dr. HELIOS Klinikum Berlin-Buch Recruiting Berlin, Germany, 13125 Contact: Herrad Baurmann, Dr. herrad.baurmann@helios-kliniken.de Principal Investigator: Herrad Baurmann, Dr. Sub-Investigator: Stephan Fuhrmann, Dr. Universitätsklinikum Bonn Recruiting Bonn, Germany, 53105 Contact: Dominik Wolf, Prof. Dr. dominik.wolf@ukb.uni-bonn.de Principal Investigator: Dominik Wolf, Prof. Dr. Sub-Investigator: Karin Mayer, Dr. Universitätsklinikum Düsseldorf Recruiting Düsseldorf, Germany, 40225 Contact: Guido Kobbe, Prof. Dr. Kobbe@med.uni-duesseldorf.de Principal Investigator: Guido Kobbe, Prof. Dr. Sub-Investigator: Thomas Schröder, PD Dr. Universitätsklinikum Essen Recruiting Essen, Germany, 45147 Contact: Joachim Göthert, Dr. Joachim.Goethert@uk-essen.de Principal Investigator: Joachim Göthert, Dr. Sub-Investigator: Jürgen Novotny, PD Dr. Klinikum Frankfurt (Oder) GmbH Not yet recruiting Frankfurt (Oder), Germany, 15236 Contact: Michael Kiehl, Prof. Dr. Contact: Olaf Hopfer, Dr. Principal Investigator: Olaf Hopfer, Dr. Sub-Investigator: Georgios Fellas Universitätsklinkum Halle Recruiting Halle (Saale), Germany, 06120 Contact: Haifa Kathrin Al-Ali, PD Dr. haifa.al-ali@uk-halle.de Principal Investigator: Haifa Kathrin Al-Ali, PD Dr. Sub-Investigator: Nadja Jäkel, Dr. University Medical Center Hamburg-Eppendorf Recruiting Hamburg, Germany, 20246 Contact: Nicolaus Kroeger, Prof. Dr. +49-40-7410-55864 n.kroeger@uke.de Contact: Marion Heinzelmann +49-40-7410-54188 mheinzel@uke.de Principal Investigator: Nicolaus Kroeger, Prof. Dr. Sub-Investigator: Christine Wolschke, Dr. Universitätsklinikum Jena Recruiting Jena, Germany, 07747 Contact: Inken Hilgendorf, PD Dr. Inken.Hilgendorf@med.uni-jena.de Principal Investigator: Inken Hilgendorf, PD Dr. Sub-Investigator: Nils Winkelmann, Dr. University Hospital Leipzig Recruiting Leipzig, Germany, 04103 Contact: Dietger Niederwieser, Prof. Dr. Dietger.Niederwieser@medizin.uni-leipzig.de Principal Investigator: Dietger Niederwieser, Prof. Dr. Sub-Investigator: Vladan Vucinic, Dr. Universitätsmedizin der Johannes Gutenberg-Universität Mainz Recruiting Mainz, Germany, 55131 Contact: Eva Wagner, Dr. eva.wagner@unimedizin-mainz.de Principal Investigator: Eva Wagner-Drouet, Dr. Sub-Investigator: Thomas Kindler, PD Dr. Universitätsmedizin Mannheim Recruiting Mannheim, Germany, 68167 Contact: Stefan Klein, PD Dr. Stefan.Klein@medma.uni-heidelberg.de Principal Investigator: Stefan Klein, PD Dr. Sub-Investigator: Andreas Reiter, Prof. Dr. Johannes Wesling Klinikum Minden Recruiting Minden, Germany, 32429 Contact: Martin Griesshammer, Prof. Dr. martin.griesshammer@muehlenkreiskliniken.de Principal Investigator: Martin Griesshammer, Prof. Dr. Sub-Investigator: Hans-Joachim Tischler, Dr. Universitätsklinikum Münster Recruiting Munster, Germany, 48149 Contact: Matthias Stelljes, Prof. Dr. Matthias.Stelljes@ukmuenster.de Principal Investigator: Eva Eßeling, Dr. Sub-Investigator: Matthias Stelljes, Prof. Dr. Klinikum Nürnberg Recruiting Nürnberg, Germany, 90419 Contact: Kerstin Schäfer-Eckart, Dr. Kerstin.Schaefer-Eckart@klinikum-nuernberg.de Principal Investigator: Kerstin Schäfer-Eckart, Dr. Sub-Investigator: Knut Wendelin, Dr, Robert-Bosch-Krankenhaus Stuttgart Recruiting Stuttgart, Germany, 70376 Contact: Martin Kaufmann, Dr. Martin.Kaufmann@rbk.de Principal Investigator: Martin Kaufmann, Dr. Sub-Investigator: Matthias Vöhringer, Dr. Universitätsmedizin Tübingen Recruiting Tübingen, Germany, 72076 Contact: Wolfgang Bethge, Prof. Dr. Wolfgang.Bethge@med.uni-tuebingen.de Principal Investigator: Wolfgang Bethge, Prof. Dr. Sub-Investigator: Christoph Faul, Dr. Universitätsklinkum Ulm Recruiting Ulm, Germany, 89081 Contact: Konstanze Döhner, Prof. Dr. Konstanze.Doehner@uniklinik-ulm.de Principal Investigator: Konstanze Döhner, Prof. Dr. Sub-Investigator: Frank Stegelmann, Dr. 收起 <<
NCT02119663	Pancreatic Cancer	Phase 3	Terminated(The safety committe... 展开 >>e found no safety issues but recommended halting the study based on a lack of efficacy in a similar trial. The sponsor terminated the trial.) 收起 <<	-	-
NCT03386214	Myelofibroses	Phase 1	Recruiting	March 31, 2021	United States, Missouri ... 展开 >> Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: Stephen Oh, M.D., Ph.D. 314-747-7960 stoh@wustl.edu Principal Investigator: Stephen Oh, M.D., Ph.D. Sub-Investigator: Amy Zhou, M.D. 收起 <<
NCT01317875	Myelofibrosis	Phase 1	Active, not recruiting	September 2020	United States, Florida ... 展开 >> Winter Park, Florida, United States, 32789 United States, Maryland Baltimore, Maryland, United States, 21229 United States, Texas Houston, Texas, United States, 77030 Austria Vienna, Austria China, Jiangsu Nanjing, Jiangsu, China China, Sichuan Chengdu, Sichuan, China China, Zhejiang Hangzhou, Zhejiang, China China Beijing, China France Angers, France Paris, France Pierre-Benite, France Germany Leipzig, Germany Italy Firenze, Italy Milano, Italy Terni, Italy Netherlands Rotterdam, Netherlands United Kingdom Belfast, United Kingdom London, United Kingdom 收起 <<
NCT02917096	Primary Myelofibrosis ... 展开 >> Secondary Myelofibrosis 收起 <<	Not Applicable	Recruiting	October 2019	United States, California ... 展开 >> City of Hope Medical Center Recruiting Duarte, California, United States, 91010 Contact: Haris Ali 626-256-4673 Principal Investigator: Haris Ali 收起 <<
NCT01375140	Myeloproliferative Diseases	Phase 2	Completed	-	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT02087059	Primary Myelofibrosis (MF)	Phase 3	Completed	-	Japan ... 展开 >> Novartis Investigative Site Nagoya-city, Aichi, Japan, 467-8602 Novartis Investigative Site Matsuyama, Ehime, Japan, 790-8524 Novartis Investigative Site Toon-city, Ehime, Japan, 791-0295 Novartis Investigative Site Fukuoka-city, Fukuoka, Japan, 812-8582 Novartis Investigative Site Kurume-city, Fukuoka, Japan, 830-0011 Novartis Investigative Site Maebashi-city, Gunma, Japan, 371-8511 Novartis Investigative Site Sapporo-city, Hokkaido, Japan, 060-8543 Novartis Investigative Site Sapporo-city, Hokkaido, Japan, 060-8648 Novartis Investigative Site Kobe-city, Hyogo, Japan, 650-0017 Novartis Investigative Site Kobe-city, Hyogo, Japan, 650-0047 Novartis Investigative Site Kumamoto City, Kumamoto, Japan, 860-8556 Novartis Investigative Site Kyoto-city, Kyoto, Japan, 606-8507 Novartis Investigative Site Tsu-city, Mie, Japan, 514-8507 Novartis Investigative Site Sendai-city, Miyagi, Japan, 980-8574 Novartis Investigative Site Miyazaki-city, Miyazaki, Japan, 889-1692 Novartis Investigative Site Okayama-city, Okayama, Japan, 700-8558 Novartis Investigative Site Hirakata-city, Osaka, Japan, 573-1191 Novartis Investigative Site OsakaSayama, Osaka, Japan, 589-8511 Novartis Investigative Site Suita-city, Osaka, Japan, 565-0871 Novartis Investigative Site Shimotsuke-city, Tochigi, Japan, 329-0498 Novartis Investigative Site Bunkyo-ku, Tokyo, Japan, 113-8431 Novartis Investigative Site Bunkyo-ku, Tokyo, Japan, 113-8519 Novartis Investigative Site Bunkyo-ku, Tokyo, Japan, 113-8603 Novartis Investigative Site Bunkyo-ku, Tokyo, Japan, 113-8677 Novartis Investigative Site Shinjuku-ku, Tokyo, Japan, 160-0023 Novartis Investigative Site Shinjuku-ku, Tokyo, Japan, 162-8666 Novartis Investigative Site Chuo-city, Yamanashi, Japan, 409-3898 Novartis Investigative Site Akita, Japan, 010-8543 Novartis Investigative Site Gifu, Japan, 501-1194 收起 <<
NCT02087059	-		Completed	-	-
NCT03373877	Myelofibrosis ... 展开 >> Primary Myelofibrosis Post-polycythemia Vera Myelofibrosis Post-essential Thrombocythemia Myelofibrosis 收起 <<	Phase 1	Recruiting	December 2019	United States, Connecticut ... 展开 >> Yale Cancer Center Recruiting New Haven, Connecticut, United States, 06511 Contact: Kris Awerkamp, BSN RN CCRP 602-358-8319 kawerkamp@td2inc.com Principal Investigator: Nikolai Podoltsev, MD PhD United States, Louisiana Ochsner Clinic Foundation Recruiting New Orleans, Louisiana, United States, 70121 Contact: Kris Awerkamp, BSN, RN 602-358-8319 kawerkamp@td2inc.com Principal Investigator: Laura Finn, MD United States, Michigan University of Michigan Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Kris Awerkamp, BSN, RN 602-358-8319 kawerkamp@td2inc.com Principal Investigator: Moshe Talpaz, MD Karmanos Cancer Institute Recruiting Detroit, Michigan, United States, 48201 Contact: Kris Awerkamp, BSN, RN 602-358-8319 kawerkamp@td2inc.com Principal Investigator: Jay Yang, MD United States, Nebraska University of Nebraska Medical Center Recruiting Omaha, Nebraska, United States, 68198 Contact: Kris Awerkamp, BSN, RN 602-358-8319 kawerkamp@td2inc.com Principal Investigator: Krishna Gundabolu, MD United States, North Carolina Duke University Medical Center Recruiting Durham, North Carolina, United States, 27710 Contact: Kris Awerkamp, BSN RN CCRP 602-358-8319 kawerkamp@td2inc.com Principal Investigator: Murat Arcasoy, MD United States, Ohio Cleveland Clinic - Taussig Cancer Institute Recruiting Cleveland, Ohio, United States, 44195 Contact: Kris Awerkamp, BSN RN CCRP 602-358-8319 kawerkamp@td2inc.com Principal Investigator: Moshe Talpaz, MD United States, Pennsylvania Abramson Cancer Center - University of Pennsylvania Recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Kris Awerkamp, BSN, RN 602-358-8319 kawerkamp@td2inc.com Principal Investigator: Elizabeth Hexner, MD United States, Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Kris Awerkamp, BSN, RN 602-358-8319 kawerkamp@td2inc.com Principal Investigator: Naveen Pemmaraju, MD Mays Cancer Center UT Health San Antonio Recruiting San Antonio, Texas, United States, 78229-3900 Contact: Kris Awerkamp, BSN, RN, CCRP 602-358-8319 kawerkamp@td2inc.com Principal Investigator: Ruben A. Mesa, MD, FACP 收起 <<
NCT02913261	Corticosteroid Refractory Acut... 展开 >>e Graft vs Host Disease 收起 <<	Phase 3	Recruiting	March 8, 2021	-
NCT00639002	Multiple Myeloma	Phase 2	Completed	-	United States, California ... 展开 >> Highland, California, United States, 92346 United States, Florida Boynton Beach, Florida, United States, 33435 United States, New York New York, New York, United States, 10011 收起 <<
NCT02475655	HIV Infections	Phase 2	Completed	-	United States, Alabama ... 展开 >> Alabama CRS Birmingham, Alabama, United States, 35294 United States, California UCLA CARE Center CRS Los Angeles, California, United States, 90035 UCSD Antiviral Research Center CRS San Diego, California, United States, 92103 Ucsf Hiv/Aids Crs San Francisco, California, United States, 94110 United States, Illinois Northwestern University CRS Chicago, Illinois, United States, 60611 United States, Missouri Washington University Therapeutics (WT) CRS Saint Louis, Missouri, United States, 63110-1010 United States, New York Weill Cornell Chelsea CRS New York, New York, United States, 10010 Weill Cornell Uptown CRS New York, New York, United States, 10065 University of Rochester Adult HIV Therapeutic Strategies Network CRS Rochester, New York, United States, 14642 United States, Ohio Cincinnati Clinical Research Site Cincinnati, Ohio, United States, 45219 Case Clinical Research Site Cleveland, Ohio, United States, 44106 United States, Pennsylvania Penn Therapeutics, CRS Philadelphia, Pennsylvania, United States, 19104 United States, Rhode Island The Miriam Hospital Clinical Research Site (TMH CRS) CRS Providence, Rhode Island, United States, 02906 United States, Tennessee Vanderbilt Therapeutics (VT) CRS Nashville, Tennessee, United States, 37204 收起 <<
NCT00509899	-		Completed	-	-
NCT02119676	CRC (Colorectal Cancer)	Phase 2	Terminated(Substudy 1 was term... 展开 >>inated for futility at interim analysis and Substudy 2 was terminated per sponsor decision.) 收起 <<	-	-
NCT02119676	-		Terminated(Substudy 1 was term... 展开 >>inated for futility at interim analysis and Substudy 2 was terminated per sponsor decision.) 收起 <<	-	-
NCT02038036	Polycythemia Vera	Phase 3	Active, not recruiting	April 8, 2020	-
NCT01644110	Primary Myelofibrosis ... 展开 >> Secondary Myelofibrosis PMF SMF Post-PV MF Post-ET MF 收起 <<	Phase 1 Phase 2	Recruiting	May 2022	Germany ... 展开 >> University of Ulm Recruiting Ulm, Germany, 89081 Contact: Konstanze Doehner, MD konstanze.doehner@uniklinik-ulm.de Principal Investigator: konstanze Doehner, Md 收起 <<
NCT00509899	Myelofibrosis ... 展开 >> Polycythemia Vera Thrombocytosis 收起 <<	Phase 1 Phase 2	Completed	-	United States, Minnesota ... 展开 >> Rochester, Minnesota, United States United States, Texas Houston, Texas, United States 收起 <<
NCT02997280	Graft Vs Host Disease	Phase 2	Recruiting	June 2019	Russian Federation ... 展开 >> First Pavlov State Medical University of St. Petersburg Recruiting Saint-Petersburg, Russian Federation, 197089 Contact: Ivan S. Moiseev, PhD +79217961951 moisiv@mail.ru Contact: Boris V. Afanasyev, Prof +78122334551 coordinatorbmt@gmail.com 收起 <<
NCT00639002	-		Completed	-	-
NCT00726232	MPN (Myeloproliferative Neopla... 展开 >>sms) 收起 <<	Phase 2	Completed	-	United States, Texas ... 展开 >> Houston, Texas, United States, 77030 Italy Bergamo, Italy Firenze, Italy Pavia, Italy 收起 <<
NCT02120417	Breast Cancer	Phase 2	Terminated(The study was termi... 展开 >>nated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation.) 收起 <<	-	-
NCT02292446	Polycythemia Vera	Phase 3	Completed	-	-
NCT01348490	MPN (Myeloproliferative Neopla... 展开 >>sms) 收起 <<	Phase 2	Active, not recruiting	November 2018	-
NCT02598297	Early Myelofibrosis With High ... 展开 >>Molecular Risk Mutations 收起 <<	Phase 3	Completed	-	-
NCT02257138	Blasts More Than 20 Percent of... 展开 >> Bone Marrow Nucleated Cells Blasts More Than 20 Percent of Peripheral Blood White Cells Myelodysplastic/Myeloproliferative Neoplasm Recurrent Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia 收起 <<	Phase 1 Phase 2	Recruiting	February 1, 2019	United States, Texas ... 展开 >> M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Farhad Ravandi-Kashani 713-745-0394 Principal Investigator: Farhad Ravandi-Kashani 收起 <<
NCT02396628	Graft vs Host Disease	Phase 2	Recruiting	March 2023	Germany ... 展开 >> Charité - Universitätsmedizin Berlin Recruiting Berlin, Germany, 13353 Principal Investigator: Igor Blau, PD Dr. Sub-Investigator: Il-Kang Na, PD Dr. Sub-Investigator: Giang Lam Vuong, Dr. Universitätsklinikum Bonn Recruiting Bonn, Germany, 53105 Principal Investigator: Dominik Wolf, Prof. Sub-Investigator: Karin Mayer, Dr. Universitätsklinikum Dresden Recruiting Dresden, Germany, 01307 Principal Investigator: Friedrich Stölzel, Dr. Sub-Investigator: Rainer Ordemann, Prof. University Medical Center Recruiting Freiburg, Germany, 79106 Contact: Nikolas von Bubnoff, Professor nikolas.bubnoff@uniklinik-freiburg.de Principal Investigator: Nikolas von Bubnoff, Professor Sub-Investigator: Robert Zeiser, Professor Universitätsklinikum Hamburg Eppendorf Recruiting Hamburg, Germany, 20246 Principal Investigator: Francis Ayuk, PD Dr. Sub-Investigator: Dietlinde Janson, Dr. Universitätsklinikum Heidelberg Recruiting Heidelberg, Germany, 69120 Principal Investigator: Peter Dreger, Prof. Sub-Investigator: Thomas Luft, PD Dr. Universitätsklinikum des Saarlandes Recruiting Homburg, Germany, 66421 Contact: Jörg T. Bittenbring, Dr. Principal Investigator: Jörg T. Bittenbring, Dr. Sub-Investigator: Niels Murawski, PD Dr. Universitätsklinikum Köln Recruiting Köln, Germany, 50937 Contact: Udo Holtick, Dr. Principal Investigator: Udo Holtick, Dr. Sub-Investigator: Christof Scheid, Prof. Sub-Investigator: Marco Herling, Dr. Universitätsklinikum Marburg Recruiting Marburg, Germany, 35043 Contact: Andreas Burchert, Prof. Principal Investigator: Andreas Burchert, Prof. Sub-Investigator: Kristina Sohlbach, Dr. Universitätsklinikum München TU rechts der Isar Recruiting München, Germany, 81675 Principal Investigator: Mareike Verbeek, Dr. Sub-Investigator: Sandra Grass, Dr. Universitätsklinikum Würzburg Recruiting Würzburg, Germany, 97080 Principal Investigator: Götz Grigoleit, Dr. Sub-Investigator: Sabrina Kraus, Dr. 收起 <<
NCT03144687	MPN (Myeloproliferative Neopla... 展开 >>sms) 收起 <<	Phase 2	Recruiting	March 2019	United States, Arizona ... 展开 >> Arizona Oncology Associates Recruiting Tempe, Arizona, United States, 85284 Contact: Study Coordinator 480-256-1664 Principal Investigator: Kasra Karamlou United States, California UC Irvine Medical Center Recruiting Orange, California, United States, 92868 Contact: Study Coordinator 714-456-5408 Principal Investigator: Angela Fleischman, MD United States, Colorado Anschutz Cancer Pavilion - University Of Colorado Recruiting Aurora, Colorado, United States, 80045 Contact: Study Coordinator 720-848-2587 Principal Investigator: Brandon McMahon United States, Connecticut Norwalk Hospital Recruiting Norwalk, Connecticut, United States, 06856 Contact: Study Coordinator 203-852-2996 Principal Investigator: Richard Frank United States, District of Columbia Georgetown University Hospital Not yet recruiting Washington, District of Columbia, United States, 20007 Contact: Study Coordinator 202-687-0116 Principal Investigator: Craig Kessler United States, Indiana Parkview Research Center Recruiting Fort Wayne, Indiana, United States, 46845 Contact: Study Coordinator 260-425-6831 Principal Investigator: Robert Manges United States, Maryland University Of Maryland - Greenebaum Cancer Center Recruiting Baltimore, Maryland, United States, 21201 Contact: Study Coordinator 410-328-6635 Principal Investigator: Duong United States, Michigan University of Michigan Health System Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Study Coordinator 734-936-3879 Principal Investigator: Moshe Talpaz, MD Karmanos Cancer Institute Recruiting Detroit, Michigan, United States, 48201 Contact: Study Coordinator 313-576-9758 Principal Investigator: Jay Yang Providence Cancer Center Recruiting Southfield, Michigan, United States, 48075 Contact: Study Coordinator 248-849-5332 Principal Investigator: Howard Terebelo United States, New Mexico University Of New Mexico Cancer Center Recruiting Albuquerque, New Mexico, United States, 87102 Contact: Study Coordinator 505-925-0379 Principal Investigator: Arana Yi United States, New York Weill Cornell Medical Centers Not yet recruiting New York, New York, United States, 10065 Contact: Study Coordinator 212-746-2389 Principal Investigator: Ellen Ritchie New York Medical College Not yet recruiting Valhalla, New York, United States, 10595 Contact: Study Coordinator 914-493-8375 Principal Investigator: Karen Seiter United States, North Carolina Duke University Medical Center Not yet recruiting Durham, North Carolina, United States, 27710 Contact: Study Coordinator 919-681-4769 Principal Investigator: Murat Arcasoy United States, Ohio Cleveland Clinic Recruiting Cleveland, Ohio, United States, 44195 Contact: Study Coordinator 216-444-9464 Principal Investigator: Aaron Gerds, MD United States, Oregon Willamette Valley Cancer Institute Recruiting Eugene, Oregon, United States, 97401 Contact: Study Coordinator 281-863-4631 Principal Investigator: Jeff Sharman, MD United States, Texas Texas Oncology San Antonio Recruiting San Antonio, Texas, United States, 78240 Contact: Study Coordinator 210-595-5680 Principal Investigator: Roger Lyons Texas Oncology - Tyler Recruiting Tyler, Texas, United States, 75702 Contact: Study Coordinator 903-579-9800 Principal Investigator: Habte Yimer United States, Virginia University of Virginia Recruiting Charlottesville, Virginia, United States, 22908 Contact: Study Coordinator 434-982-3927 Principal Investigator: Michael Keng, MD 收起 <<
NCT00638378	Prostate Cancer	Phase 2	Terminated(According to the pr... 展开 >>otocol, the sponsor terminated the study after it was determined that less than 2 of the first 22 patients showed a PSA50 response.) 收起 <<	-	United States, California ... 展开 >> Highland, California, United States Montebello, California, United States Mountain View, California, United States United States, Illinois Galesburg, Illinois, United States United States, Kansas Overland Park, Kansas, United States Wichita, Kansas, United States United States, Michigan Grand Rapids, Michigan, United States United States, Missouri Jefferson City, Missouri, United States United States, Montana Great Falls, Montana, United States, 59405 United States, New Jersey Cherry Hill, New Jersey, United States United States, New York Staten Island, New York, United States United States, North Dakota Bismarck, North Dakota, United States United States, Pennsylvania Bethlehem, Pennsylvania, United States United States, South Carolina Sumter, South Carolina, United States United States, Washington Lacey, Washington, United States 收起 <<
NCT02131584	Chronic Lymphocytic Leukemia ... 展开 >> Fatigue 收起 <<	Phase 2	Active, not recruiting	September 30, 2022	United States, Texas ... 展开 >> M D Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01431209	Recurrent Diffuse Large B-Cell... 展开 >> Lymphoma Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma Refractory Diffuse Large B-Cell Lymphoma Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma 收起 <<	Phase 2	Active, not recruiting	December 2019	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center Bethesda, Maryland, United States, 20892 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Nebraska University of Nebraska Medical Center Omaha, Nebraska, United States, 68198 收起 <<
NCT02436135	Myelofibrosis	Phase 1	Completed	-	United States, California ... 展开 >> Stanford Hospital and Clinics Stanford, California, United States, 94305 United States, Michigan University of Michigan Health System Ann Arbor, Michigan, United States, 48109 收起 <<
NCT02955940	Pancreatic Cancer ... 展开 >> Colorectal Cancer (CRC) Breast Cancer Lung Cancer 收起 <<	Phase 2	Enrolling by invitation	November 2019	United States, Kentucky ... 展开 >> University of Louisville Louisville, Kentucky, United States, 40202 United States, New York New York Oncology Hematology PC Hudson, New York, United States, 12534 United States, Texas U of Texas M.D. Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT02076191	Myeloproliferative Neoplasms	Phase 1 Phase 2	Active, not recruiting	December 2018	United States, Missouri ... 展开 >> Washington University of St. Louis Saint Louis, Missouri, United States, 63110 United States, New York Roswell Park Cancer Institute Buffalo, New York, United States, 14263 Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 Columbia University Medical Center New York, New York, United States, 10032 Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 United States, North Carolina Wake Forest University Baptist Medical Center Winston-Salem, North Carolina, United States, 27157 United States, Ohio Cleveland Clinic Taussig Cancer Center Institute Cleveland, Ohio, United States, 44195 United States, Pennsylvania University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 收起 <<
NCT00638378	-		Terminated(According to the pr... 展开 >>otocol, the sponsor terminated the study after it was determined that less than 2 of the first 22 patients showed a PSA50 response.) 收起 <<	-	-
NCT03701698	Acute GVHD	Phase 2	Not yet recruiting	October 31, 2021	China, Shanghai ... 展开 >> Shanghai General Hospital Active, not recruiting Shanghai, Shanghai, China, 200080 收起 <<
NCT01562873	Breast Cancer	Phase 2	Terminated(Not enough response... 展开 >>s to continue treatment.) 收起 <<	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 收起 <<
NCT01776723	Myelomonocytic Leukemia	Phase 1 Phase 2	Active, not recruiting	April 2020	United States, Florida ... 展开 >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 United States, Maryland Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, United States, 21287 United States, Massachusetts Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, New York Weill Medical College of Cornell New York, New York, United States, 10021 United States, Ohio Cleveland Clinic Cleveland, Ohio, United States, 44106 收起 <<
NCT01562873	-		Terminated(Not enough response... 展开 >>s to continue treatment.) 收起 <<	-	-
NCT02400463	Hemophagocytic Syndrome (HPS)	Early Phase 1	Recruiting	November 2018	United States, Michigan ... 展开 >> University of Michigan Comprehensive Cancer Center Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Ryan Wilcox, M.D. 734-615-1482 rywilcox@umich.edu Principal Investigator: Ryan Wilcox, M.D. 收起 <<
NCT02966353	Primary Myelofibrosis ... 展开 >> Post-Polycythemia Vera-Myelofibrosis Post-Essential Thrombocythemia Myelofibrosis 收起 <<	Phase 2	Active, not recruiting	February 15, 2019	Austria ... 展开 >> Novartis Investigative Site Vienna, Austria, A-1090 Belgium Novartis Investigative Site Antwerpen, Belgium, 2060 Novartis Investigative Site Leuven, Belgium, 3000 Bulgaria Novartis Investigative Site Sofia, Bulgaria, 1413 Novartis Investigative Site Sofia, Bulgaria, 1756 Canada, British Columbia Novartis Investigative Site Vancouver, British Columbia, Canada, V5Z 1M9 Germany Novartis Investigative Site Halle/S., Germany, 06120 Greece Novartis Investigative Site Thessaloniki, GR, Greece, 570 10 Novartis Investigative Site Athens, Greece, 11527 Italy Novartis Investigative Site Bologna, BO, Italy, 40138 Novartis Investigative Site Firenze, FI, Italy, 50134 Novartis Investigative Site Palermo, PA, Italy, 90127 Japan Novartis Investigative Site Bunkyo-ku, Tokyo, Japan, 113-8431 Russian Federation Novartis Investigative Site Moscow, Russian Federation, 125167 Novartis Investigative Site Moscow, Russian Federation, 129110 Novartis Investigative Site Petrozavodsk, Russian Federation, 185019 Spain Novartis Investigative Site Barcelona, Catalunya, Spain, 08036 Novartis Investigative Site Alicante, Comunidad Valenciana, Spain, 03010 Novartis Investigative Site Santiago de Compostela, Galicia, Spain, 15706 Turkey Novartis Investigative Site Istanbul, Turkey, 34093 Novartis Investigative Site Kocaeli, Turkey, 41380 收起 <<
NCT02091752	Primary Myelofibrosis	Phase 2	Terminated(The study was termi... 展开 >>nated due to low enrollment.) 收起 <<	-	Germany ... 展开 >> Novartis Investigative Site Leipzig, Germany, 04103 Italy Novartis Investigative Site Firenze, FI, Italy, 50134 Spain Novartis Investigative Site Madrid, Spain, 28034 收起 <<
NCT02253277	Chronic Myeloid Leukemia	Phase 1 Phase 2	Completed	-	Germany ... 展开 >> Novartis Investigative Site Berlin, Germany, 13353 Novartis Investigative Site Frankfurt, Germany, 60590 Novartis Investigative Site Freiburg, Germany, 79106 Novartis Investigative Site Jena, Germany, 07740 Novartis Investigative Site Leipzig, Germany, 04103 Novartis Investigative Site Mannheim, Germany, 68169 收起 <<
NCT02091752	-		Terminated(The study was termi... 展开 >>nated due to low enrollment.) 收起 <<	-	-
NCT01251965	Leukemia	Phase 1 Phase 2	Completed	-	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT00726232	-		Completed	-	-
NCT01702064	Chronic Phase Chronic Myeloid ... 展开 >>Leukemia 收起 <<	Phase 1	Active, not recruiting	March 2019	United States, Florida ... 展开 >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 收起 <<
NCT02876302	Inflammatory Breast Cancer (IB... 展开 >>C) 收起 <<	Phase 2	Recruiting	February 2024	United States, Maryland ... 展开 >> Johns Hopkins University Recruiting Baltimore, Maryland, United States, 21287 Contact: Vered Stearns, MD vstearn1@jhmi.edu Johns Hopkins at Green Spring Station Recruiting Lutherville, Maryland, United States, 21093 Contact: Vered Stearns, MD Vstearn1@jhmi.edu United States, Massachusetts Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Beth Overmoyer, MD, FACP 617-632-4056 bovermoyer@partners.org Principal Investigator: Beth Overmoyer, MD, FACP United States, Michigan University of Michigan Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Catherine Van Poznak, MD cvanpoz@med.umich.edu United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Tufia Haddad, MD Haddad.Tufia@mayo.edu United States, North Carolina Duke University Medical Center Recruiting Durham, North Carolina, United States, 27710 Contact: Jeremy Force, MD Jeremy.force@duke.edu United States, Pennsylvania University of Pennslyvania Recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Amy Clark, MD Clarkamy@mail.upenn.edu United States, Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Naoto Ueno, MD Nueno@mdanderson.org 收起 <<
NCT01340651	-		Completed	-	-
NCT01340651	Myelofibrosis	Phase 2	Completed	-	United States, Arizona ... 展开 >> Scottsdale, Arizona, United States United States, Florida Winter Park, Florida, United States United States, Texas Houston, Texas, United States, TX 收起 <<
NCT02155465	Lung Cancer	Phase 1 Phase 2	Completed	-	United States, New Jersey ... 展开 >> Memoral Sloan Kettering Cancer Center Basking Ridge, New Jersey, United States United States, New York Memorial Sloan Kettering Cancer Center @ Suffolk Commack, New York, United States, 11725 Memorial Sloan Kettering West Harrison Harrison, New York, United States, 10604 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Memorial Sloan Kettering at Mercy Medical Center Rockville Centre, New York, United States Memoral Sloan Kettering Cancer Center at Phelps Sleepy Hollow, New York, United States, 10591 收起 <<
NCT01445769	Primary Myelofibrosis ... 展开 >> Post-Polycythemia Vera Myelofibrosis Post-Essential Thrombocythemia Myelofibrosis 收起 <<	Phase 2	Completed	-	United States, California ... 展开 >> Highland, California, United States La Jolla, California, United States Los Angeles, California, United States United States, Florida Jacksonville, Florida, United States Orange City, Florida, United States Winter Park, Florida, United States United States, Georgia Atlanta, Georgia, United States Augusta, Georgia, United States United States, Iowa Iowa City, Iowa, United States United States, Maryland Baltimore, Maryland, United States United States, Michigan Ann Arbor, Michigan, United States Southfield, Michigan, United States United States, New Jersey Morristown, New Jersey, United States United States, New York Armonk, New York, United States United States, North Carolina Hickory, North Carolina, United States United States, Ohio Canton, Ohio, United States United States, Pennsylvania Hazelton, Pennsylvania, United States Hershey, Pennsylvania, United States United States, South Carolina Charleston, South Carolina, United States United States, South Dakota Sioux Falls, South Dakota, United States United States, Texas San Antonio, Texas, United States 收起 <<
NCT01445769	-		Completed	-	-
NCT03610971	Chronic Phase Chronic Myeloid ... 展开 >>Leukemia Chronic Myeloid Leukemia, Chronic Phase 收起 <<	Phase 2	Not yet recruiting	January 2022	United States, Florida ... 展开 >> H. Lee Moffitt Cancer Center and Research Institute Not yet recruiting Tampa, Florida, United States, 33612 Contact: Anthony McLaughlin 813-745-5941 anthony.mclaughlin@moffitt.org Contact: Kendra Sweet, M.D. 813-745-8986 kendra.sweet@moffitt.org Principal Investigator: Kendra Sweet, M.D. 收起 <<
NCT01693601	Myelofibrosis	Phase 1 Phase 2	Active, not recruiting	February 2019	United States, New York ... 展开 >> Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 收起 <<
NCT02015208	Chronic Lymphocytic Leukemia	Phase 1 Phase 2	Completed	-	Canada, Ontario ... 展开 >> Sunnybrook Odette Cancer Center Toronto, Ontario, Canada, M4N3M5 收起 <<
NCT03571321	Acute Lymphoblastic Leukemia ... 展开 >> ALL, Childhood ALL 收起 <<	Phase 1	Not yet recruiting	September 5, 2024	United States, Illinois ... 展开 >> University of Chicago Medical Center Not yet recruiting Chicago, Illinois, United States, 60637 Contact: Howie Weiner 773-702-2084 hweiner@medicine.bsd.uchicago.edu Contact: Peggy Green, RN (773) 702-0267 mgreen@medicine.bsd.uchicago.edu Principal Investigator: Emily Currant, MD 收起 <<
NCT03069326	Myelofibrosis	Phase 2	Recruiting	February 2019	United States, New Jersey ... 展开 >> Memorial Sloan Kettering Monmouth Recruiting Middletown, New Jersey, United States, 07748 Contact: Raajit Rampal, MD, PhD 212-639-2194 United States, New York Memorial Sloan Kettering Commack Recruiting Commack, New York, United States, 11725 Contact: Raajit Rampa, MD, PhD 212-639-2194 Memorial Sloan Kettering Westchester Recruiting Harrison, New York, United States, 10604 Contact: Raajit Rampal, MD, PhD 212-639-2194 Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Raajit Rampal, MD, PhD 212-639-2194 Contact: Ellin Berman, MD 212-639-7762 Principal Investigator: Raajit Rampal, MD, PhD Memorial Sloan Kettering Rockville Centre Recruiting Rockville Centre, New York, United States, 11570 Contact: Raajit Rampal, MD, PhD 212-639-2194 United States, Texas Md Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Prithvira Bose, MD 713-792-7747 Principal Investigator: Prithvira Bose, MD 收起 <<
NCT01950780	Alopecia Areata	Phase 2	Completed	-	United States, New York ... 展开 >> Columbia University Medical Center, Department of Dermatology New York, New York, United States, 10032 收起 <<
NCT02613598	Hodgkin's Lymphoma ... 展开 >> Lymphoma, Non-Hodgkin 收起 <<	Phase 1	Recruiting	October 2021	United States, Michigan ... 展开 >> University of Michgan Comprehensive Cancer Center Recruiting Ann Arbor, Michigan, United States, 48187 Contact: Tycel Phillips, M.D. 734-232-2883 tycelp@umich.edu Principal Investigator: Tycel Phillips, M.D. 收起 <<
NCT02066532	Metastatic Breast Cancer ... 展开 >> Breast Carcinoma HER-2 Positive Breast Cancer 收起 <<	Phase 1 Phase 2	Recruiting	December 2018	United States, New York ... 展开 >> Mount Sinai Medical Center Recruiting New York, New York, United States, 10029 Contact: Amy Tiersten, MD 212-241-2299 amy.tiersten@mssm.edu Principal Investigator: Amy Tiersten, MD Columbia University Medical Center Recruiting New York, New York, United States, 10032 Contact: Kevin Kalinsky, MD, MS 212-305-1945 KK2693@cumc.columbia.edu Contact: Dan Otap, CCRP 212-342-3970 DO2267@cumc.columbia.edu Principal Investigator: Kevin Kalinsky, MD, MS New York Hospital-Weill Cornell Medical Center Recruiting New York, New York, United States, 10065 Contact: Tessa Cigler, MD 212-821-0644 elc2007@med.cornell.edu Principal Investigator: Tessa Cigler, MD Montefiore Medical Center Recruiting New York, New York, United States, 10461 Contact: Della Makower, MD 718-405-8529 dmakower@montefiore.org Principal Investigator: Della Makower, MD 收起 <<
NCT03674047	Other Cancer	Phase 2	Not yet recruiting	March 31, 2023	United States, Massachusetts ... 展开 >> Dana Farber Cancer Institute Not yet recruiting Boston, Massachusetts, United States, 02214 Contact: Zachariah DeFilipp, MD 617-724-4000 zdefilipp@mgh.harvard.edu Principal Investigator: Zachariah DeFilipp, MD 收起 <<
NCT03491215	Acute Graft Versus Host Diseas... 展开 >>e 收起 <<	Phase 1 Phase 2	Recruiting	July 1, 2022	Australia, Queensland ... 展开 >> Novartis Investigative Site Recruiting Brisbane, Queensland, Australia, 4101 Australia, Victoria Novartis Investigative Site Recruiting Parkville, Victoria, Australia, 3052 Belgium Novartis Investigative Site Recruiting Bruxelles, Belgium, 1200 Novartis Investigative Site Recruiting Leuven, Belgium, 3000 Italy Novartis Investigative Site Recruiting Genova, GE, Italy, 16147 Slovenia Novartis Investigative Site Recruiting Ljubljana, Slovenia, 1000 Spain Novartis Investigative Site Recruiting Barcelona, Cataluña, Spain, 08025 Novartis Investigative Site Recruiting Madrid, Spain, 28009 收起 <<
NCT03222609	Myelofibrosis (MF)	Phase 2	Recruiting	June 11, 2021	United States, Alabama ... 展开 >> UAB Comprehensive Cancer Cente /ID# 165464 Recruiting Birmingham, Alabama, United States, 35217 United States, California Ucsd /Id# 164084 Recruiting La Jolla, California, United States, 92037 Usc /Id# 164095 Recruiting Los Angeles, California, United States, 90033 United States, Florida Mayo Clinic /ID# 164201 Recruiting Jacksonville, Florida, United States, 32224 Moffitt Cancer Center /ID# 164082 Recruiting Tampa, Florida, United States, 33612 United States, Illinois University of Chicago /ID# 164115 Recruiting Chicago, Illinois, United States, 60637 United States, Indiana Indiana Blood & Marrow Transpl /ID# 165075 Recruiting Indianapolis, Indiana, United States, 46237 United States, Massachusetts Dana-Farber Cancer Institute /ID# 162675 Recruiting Boston, Massachusetts, United States, 02215 United States, Michigan Henry Ford Hospital /ID# 162682 Recruiting Detroit, Michigan, United States, 48202 United States, New York Weill Cornell Medical College /ID# 162679 Recruiting New York, New York, United States, 10021 United States, Texas MD Anderson Cancer Center /ID# 162683 Recruiting Houston, Texas, United States, 77030 UT Health Cancer Center /ID# 164094 Recruiting San Antonio, Texas, United States, 78229 United States, Utah University of Utah /ID# 164116 Recruiting Salt Lake City, Utah, United States, 84112-5500 United Kingdom Guy's and St Thomas' NHS Found /ID# 164110 Recruiting London, London, City Of, United Kingdom, SE1 9RT Christie NHS Foundation Trust /ID# 164111 Recruiting Manchester, United Kingdom, M20 4BX 收起 <<
NCT02469974	Myelofibrosis ... 展开 >> MF 收起 <<	Not Applicable	Withdrawn(no enrollments)	-	-
NCT03613428	Acute T Cell Leukemia	Phase 1 Phase 2	Not yet recruiting	March 30, 2021	-
NCT02723994	Leukemia	Phase 2	Recruiting	May 2024	-
NCT03745651	Atopic Dermatitis	Phase 3	Recruiting	September 2020	United States, Florida ... 展开 >> San Marcus Research Clinic Inc Recruiting Miami, Florida, United States, 33015 Well Pharma Medical Research Corporation Not yet recruiting Miami, Florida, United States, 33143 Forward Clinical Trials Inc Not yet recruiting Tampa, Florida, United States, 33624 United States, Georgia Clinical Research Atlanta Not yet recruiting Stockbridge, Georgia, United States, 30281 United States, Kentucky Derm Research LLC Not yet recruiting Louisville, Kentucky, United States, 40217 Dermatology Specialists PSC Not yet recruiting Louisville, Kentucky, United States, 40241 United States, New Hampshire ActivMed Practices & Research Inc Not yet recruiting Portsmouth, New Hampshire, United States, 03801 United States, New Jersey Hassman Research Institute Not yet recruiting Berlin, New Jersey, United States, 08009 United States, Ohio Synexus Clinical Research US, Inc. - Cincinnati Not yet recruiting Cincinnati, Ohio, United States, 45236 United States, Pennsylvania Paddington Testing Company Inc Not yet recruiting Philadelphia, Pennsylvania, United States, 19103 United States, South Carolina Synexus Clinical Research US, Inc. - Anderson Not yet recruiting Anderson, South Carolina, United States, 29621 United States, Texas Clinical Trials of Texas Incorporated Not yet recruiting San Antonio, Texas, United States, 78229 Center for Clinical Studies Not yet recruiting Webster, Texas, United States, 77598 United States, Virginia Clinical Research Partners LLC Not yet recruiting Henrico, Virginia, United States, 23233 United States, Washington Dermatology Specialists of Spokane Not yet recruiting Spokane, Washington, United States, 99204 收起 <<
NCT03112603	Graft-versus-host Disease (GVH... 展开 >>D) 收起 <<	Phase 3	Recruiting	January 2022	-
NCT03153982	Head and Neck Squamous Cell Ca... 展开 >>rcinoma 收起 <<	Phase 2	Not yet recruiting	September 29, 2020	United States, Arizona ... 展开 >> University of Arizona Cancer Center Not yet recruiting Tucson, Arizona, United States, 85724 Contact: Clinical Trials Office 866-278-1554 UACC-C3@uacc.arizona.edu Sub-Investigator: Julie Bauman, MD United States, California UCSF Helen Diller Family Comprehensive Cancer Center Not yet recruiting San Francisco, California, United States, 94131 Contact: Kyusun Cha, CCRC 415-502-3081 Kyusun.Cha@ucsf.edu 收起 <<
NCT02973711	Leukemia, Chronic Myeloid	Phase 1 Phase 2	Recruiting	April 2021	United States, Michigan ... 展开 >> The University of Michigan Comprehensive Cancer Center Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Patrick Burke, M.D. 734-647-8921 pwburke@umich.edu Principal Investigator: Patrick Burke, M.D. United States, North Carolina Wake Forest University Health Sciences Not yet recruiting Winston-Salem, North Carolina, United States, 27157 Contact: Rupali Bhave, M.D. 336-713-0864 rbhave@wakehealth.edu Contact: Megan Brown-Farmer 336-713-6913 mebrown@wakehealth.edu 收起 <<
NCT02953678	Graft-versus-host Disease (GVH... 展开 >>D) 收起 <<	Phase 2	Active, not recruiting	June 2020	-
NCT03745638	Atopic Dermatitis	Phase 3	Recruiting	September 2020	-
NCT03147742	-		-	-	United States, Florida ... 展开 >> Blood & Marrow Transplant Center Orlando, Florida, United States, 32804 Principal Investigator: Dr. Steven Goldstein United States, Kansas Cancer Center of Kansas Wichita, Kansas, United States, 67214 Principal Investigator: Dr. Shaker Dakhil United States, Massachusetts Massachusetts General Hospital Boston, Massachusetts, United States, 02215 Principal Investigator: Dr. Yin-Bin Chen United States, Michigan University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States, 48109-5271 Principal Investigator: Dr. Sarah Anand United States, New Jersey Hackensack University Medical Center Hackensack, New Jersey, United States, 07601 Principal Investigator: Dr. Alfred Gillio United States, New York Weill Cornell Medical College New York, New York, United States, 10021 Principal Investigator: Dr. Tsiporah Shore Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Principal Investigator: Dr. Miguel-Angel Perales United States, Oregon Oregon Health & Science University Portland, Oregon, United States, 97239 Principal Investigator: Dr. Rachel Cook United States, Pennsylvania Gettysburg Cancer Center Gettysburg, Pennsylvania, United States, 17325 Principal Investigator: Dr. Satish Shah Allegheny Health Network Cancer Institute Pittsburgh, Pennsylvania, United States, 15224 Principal Investigator: Dr. Anna Koget United States, South Carolina Greenville Health System Cancer Institute Greenville, South Carolina, United States, 29615 Principal Investigator: Dr. Suzanne Fanning United States, South Dakota Avera Research Institute Sioux Falls, South Dakota, United States, 57105 Principal Investigator: Dr. Vinod Parameswaran United States, Texas Medical City Dallas Hospital Dallas, Texas, United States, 75230 Principal Investigator: Dr. Vikas Bhushan United States, Washington Fred Hutchinson Cancer Research Center Seattle, Washington, United States, 98109-1024 Principal Investigator: Dr. Paul Carpenter United States, Wisconsin Medical College of Wisconsin Milwaukee, Wisconsin, United States, 53226 Principal Investigator: Dr. Parameswaran Hari 收起 <<
NCT03110822	Multiple Myeloma	Phase 1	Recruiting	May 2020	United States, California ... 展开 >> Comprehensive Blood and Cancer Center Recruiting Bakersfield, California, United States, 93309-0633 Contact: Nicole Henry 661-862-8548 nhenry@cbccusa.com Principal Investigator: Ravindranath Patel, MD California Cancer Associates for Research & Excellence (cCARE) Recruiting Encinitas, California, United States, 92024 Contact: Daniela Slavin, PhD 760-452-3909 dslavin@ccare.com Principal Investigator: Alberto Bessudo, MD Robert A. Moss, M.D., F.A.C.P., Inc. Recruiting Fountain Valley, California, United States, 92708 Contact: Helen Tam 714-641-1128 helen.tam@sbcglobal.net Principal Investigator: Robert A Moss, MD Pacific Cancer Care Recruiting Monterey, California, United States, 93940 Contact: Dorothy Tenney 831-375-4105 dtenney@pacificcancercare.com Principal Investigator: Laura Stampleman, MD Sansum Clinic- Ridley-Tree Cancer Center Recruiting Santa Barbara, California, United States, 93105 Contact: Heidi Heitkamp, PhD 805-879-5091 hheitkam@ridleytreecc.org Principal Investigator: Daniel R Greenwald, MD James R. Berenson M.D. Inc. Recruiting West Hollywood, California, United States, 90069 Contact: Regina Swift, R.N 310-623-1227 rswift@berensononcology.com Principal Investigator: James R Berenson, MD United States, Florida Millennium Oncology Research Clinic Recruiting Pembroke Pines, Florida, United States, 33024 Contact: Maria Contreras, MD 954-266-7885 mcontreras@millenniumoncologyfl.com Principal Investigator: Isaac Levy, MD United States, Maryland Regional Cancer Care Associates (RCCA) MD, LLC Recruiting Bethesda, Maryland, United States, 20817 Contact: Natalie Bongiorno, RN 301-571-2016 nbongiorno@regionalcancercare.org Principal Investigator: Ralph Boccia, MD 收起 <<
NCT02593929	Head and Neck Squamous Cell Ca... 展开 >>rcinoma 收起 <<	Early Phase 1	Withdrawn	-	-
NCT01790295	Primary Myelofibrosis ... 展开 >> Post Polycythemia Vera Myelofibrosis Post Essential Thrombocythemia Myelofibrosis 收起 <<	Phase 2	Active, not recruiting	February 2021	United States, Georgia ... 展开 >> Emory Hospital Atlanta, Georgia, United States, 30322 United States, Illinois Northwestern University, Robert h. Lurie Comprehensive Cancer Center Chicago, Illinois, United States, 60611 United States, Kansas University of Kansas Cancer Center Westwood, Kansas, United States, 66205 United States, New York Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 United States, North Carolina Wake Forest Baptist Medical Center Winston-Salem, North Carolina, United States, 27103 United States, Ohio Ohio State University Columbus, Ohio, United States, 43210 Canada Princess Margaret Cancer Centre, University of Toronto Toronto, Canada, M5G 2M9 United Kingdom University of Oxford Oxford, United Kingdom, OX3 9DS 收起 <<
NCT02267278	Myeloproliferative Diseases	Phase 2	Completed	-	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT03616184	Graft-versus-host-disease (GVH... 展开 >>D) 收起 <<	Phase 2	Recruiting	April 2024	United States, Nebraska ... 展开 >> University of Nebraska Medical Center Recruiting Omaha, Nebraska, United States, 68198 Contact: Penny Nurse Coordinator, RN 402-559-4596 收起 <<
NCT03681561	Hodgkin Lymphoma	Phase 1 Phase 2	Recruiting	March 2024	United States, Minnesota ... 展开 >> University of Minnesota Recruiting Minneapolis, Minnesota, United States, 55455 Contact: Erin Zielinski 612-624-0937 eezielin@umn.edu Principal Investigator: Veronika Bachanova, MD 收起 <<
NCT01895842	Leukemia	Phase 1	Active, not recruiting	February 2021	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT03123588	MPN (Myeloproliferative Neopla... 展开 >>sms) 收起 <<	Phase 2	Recruiting	June 2020	-
NCT03514069	Glioma Gliobl... 展开 >>astoma 收起 <<	Phase 1	Recruiting	December 2020	United States, Ohio ... 展开 >> Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Recruiting Cleveland, Ohio, United States, 44195 Contact: Manmeet Ahluwalia, MD 866-223-8100 CancerCenterResearch@ccf.org Principal Investigator: Manmeet Ahluwalia, MD 收起 <<
NCT02493530	Myelofibrosis ... 展开 >> Polycythemia Vera 收起 <<	Phase 1	Recruiting	December 2019	United States, Arizona ... 展开 >> Mayo Clinic - Arizona Recruiting Phoenix, Arizona, United States, 85054 Contact: Clinical Trials Office 855-776-0015 Principal Investigator: Ruben Mesa, MD United States, Colorado University of Colorado Cancer Center Recruiting Aurora, Colorado, United States, 80045 Contact: Clinical Trials Office 720-848-0018 Principal Investigator: Daniel A Pollyea, MD, MS United States, Tennessee Vanderbilt-Ingram Cancer Center Recruiting Nashville, Tennessee, United States, 37232 Contact: Clinical Trials Office 800-811-8480 Principal Investigator: Michael R Savona, MD United States, Wisconsin Medical College of Wisconsin Recruiting Milwaukee, Wisconsin, United States, 53226 Contact: Clinical Trials Office 414-805-1118 Principal Investigator: Laura C. Michaelis, MD 收起 <<
NCT03286530	Acute Myeloid Leukemia ... 展开 >> Acute Myeloid Leukemia in Remission Allogeneic Stem Cell Transplantation 收起 <<	Phase 2	Recruiting	September 1, 2024	United States, Massachusetts ... 展开 >> Beth Israel Deaconess Medical Center Recruiting Boston, Massachusetts, United States, 02115 Contact: Myrna Nahas, MD 617-667-9920 Principal Investigator: Myrna Nahas, MD Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02115 Contact: Gabriella Hobbs, MD 617-726-8748 Principal Investigator: Gabriella Hobbs, MD United States, Missouri Washington University Recruiting Saint Louis, Missouri, United States, 63130 Contact: Mark Schroeder, MD markschroeder@wustl.edu Principal Investigator: Mark Schroeder, MD United States, Ohio The Ohio State University Recruiting Columbus, Ohio, United States, 43210 Contact: Sumithira Vasu, MBBS Sumithira.Vasu@osumc.edu Principal Investigator: Sumithira Vasu, MBBS United States, Tennessee Vanderbilt University Recruiting Nashville, Tennessee, United States, 37235 Contact: Michael Byrne, MD Michael.Byrne@vanderbilt.edu Principal Investigator: Michael Byrne, MD 收起 <<
NCT03041636	Malignant Neoplasms Stated as ... 展开 >>Primary Lymphoid Haematopoietic Other Diseases of Blood and Blood-Forming Organs Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma 收起 <<	Phase 2	Recruiting	March 2021	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact zestrov@mdanderson.org 收起 <<
NCT03427866	Myelofibrosis	Phase 2	Recruiting	September 30, 2021	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02214 Contact: Meridith E. Bailey, MD 617-643-4970 mebailey@partners.org Principal Investigator: Gabriela Hobbs, MD United States, Tennessee Vanderbilt University Recruiting Nashville, Tennessee, United States, 37235 Contact: Michael Byrne, DO Michael.Byrne@vanderbilt.edu Principal Investigator: Michael Byrne, DO 收起 <<
NCT03722407	Chronic Myelomonocytic Leukemi... 展开 >>a Leukemia 收起 <<	Phase 2	Not yet recruiting	February 1, 2024	United States, Florida ... 展开 >> H. Lee Moffitt Cancer Center and Research Institute Not yet recruiting Tampa, Florida, United States, 33612 Contact: Anthony McLaughlin 813-745-5941 Anthony.McLaughlin@moffitt.org Principal Investigator: Eric Padron, MD Sub-Investigator: Rami Komrokji, MD Sub-Investigator: Alan F List, MD Sub-Investigator: Jeffrey E Lancet, MD Sub-Investigator: Kendra Sweet, MD Sub-Investigator: Bijal Shah, MD Sub-Investigator: David Sallman, MD Sub-Investigator: Chetasi Talati, MD Sub-Investigator: Andrew Kuykendall, MD Sub-Investigator: Maria Balasis, BS Sub-Investigator: Brooke Fridley, PhD 收起 <<
NCT02784496	Myelofibrosis	Phase 2	Active, not recruiting	September 2020	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT02928978	Ductal Carcinoma In Situ ... 展开 >> Atypical Lobular Hyperplasia Atypical Ductal Hyperplasia Lobular Carcinoma In Situ 收起 <<	Phase 2	Recruiting	January 2020	United States, Texas ... 展开 >> Baylor College of Medicine Recruiting Houston, Texas, United States, 77030 Contact: Kristen Otte 713-798-8874 clinical-research@breastcenter.tmc.edu Principal Investigator: Julie Nangia, M.D. Sub-Investigator: Mothaffar Rimawi, M.D. Sub-Investigator: Matthew Ellis, M.D. Sub-Investigator: Maryam Nemati Shaefee, M.D. Sub-Investigator: C. Kent Osborne, M.D. Sub-Investigator: Angela Coscio, M.D. 收起 <<
NCT02912754	Leukemia, Lymphocytic, Chronic... 展开 >>, B-Cell 收起 <<	Phase 1 Phase 2	Not yet recruiting	August 2019	Canada, Ontario ... 展开 >> Sunnybrook Odette Cancer Center Not yet recruiting Toronto, Ontario, Canada, M4N 3M5 Contact: Geetha Geetha Yogendran, BSc 416-480-5000 ext 89565 geetha.yogendran@sunnybrook.ca Contact: Lindsay McCaw, MSc 416-480-6100 ext 4244 lindsay.mccaw@sunnybrook.ca Principal Investigator: david e spaner, MD Sunnybrook Odette Cancer Center Toronto, Ontario, Canada, M4N3M5 收起 <<
NCT02809976	Vitiligo	Phase 2	Completed	-	United States, Massachusetts ... 展开 >> Tufts Medical Center Boston, Massachusetts, United States, 02111 收起 <<
NCT02041429	Recurrent Breast Cancer ... 展开 >> Metastatic Breast Cancer 收起 <<	Phase 1 Phase 2	Active, not recruiting	January 2021	United States, Massachusetts ... 展开 >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 收起 <<

靶点	JAK1 JAK1, IC50:3.3 nM JAK2 JAK2, IC50:2.8 nM
描述	JAK2 (Janus kinase 2) is a non-receptor tyrosine kinase. The mutation of it, JAK2^V617F, which activates JAK2 signaling, is discovered in patients with myeloproliferative neoplasms^[2]. Ruxolitinib, also called as INCB018424, is the first potent, selective, oral JAK1/JAK2 inhibitor to enter the clinic with IC₅₀ values of 3.3 nM and 2.8 nM (measured by homogeneous time-resolved fluorescence assay), respectively. A dose-dependent reduction in the phosphorylated forms of JAK2, STAT5 and ERK1/2 can be seen in Ba/F3-EpoRJAK2^V617F cells treated with ruxolitinib, which has constitutive phosphorylation of JAK2 as well as downstream targets. Ruxolitinib inhibits hematopoietic progenitor cell proliferation in primary MPN patient samples. Orally treatment of ruxolitinib can improve viability and splenomegaly in a JAK2^V617F-driven mouse model of malignant disease^[1]. Ruxolitinib is mainly used in treatment of myelofibrosis and autoimmune diseases due its anti-inflammatory and immunomodulating activity, such as affecting DC differentiation and function of leading to impaired T-cell activation significantly^[3].
作用机制	Ruxolitinib binds in the ATP binding pocket of the kinase domain in its active configuration.^[4]

Dose	Mice: min = 50 mg/kg^[5], max = 150 mg/kg^[6]
Administration	p.o.

CAS号	941678-49-5
分子式	C₁₇H₁₈N₆
分子量	306.365

别名	鲁索替尼 ;INCB18424;INCB 018424
运输	蓝冰

A549		Growth Inhibition Assay		IC50=0.04 μM	25213670
A549/DDP		Growth Inhibition Assay		IC50=0.22 μM	25213670
A549/DDP	30 nM	Function Assay	48 h	Down-regulation of STAT3 phosphorylation	25213670
A549/DDP	30 nM	Apoptosis Assay	48 h	Induction of apoptosis	25213670
BaF3	80 nM	Kinase Assay	6 h	Reduces the phosphorylation of STAT5 in JAK2V617F-mutated BAF3-EPOR cell	24237791
CMK		Growth Inhibition Assay		Inhibition of CMK carrying the JAK3A572V mutation cell proliferation	25352124
CMK		Growth Inhibition Assay		Inhibition of CMK carrying the JAK3A63D mutation cell proliferation with IC50 of 0.163 μM	25352124
CMK		Growth Inhibition Assay		Inhibition of CMK carrying the WT JAK cell proliferation with IC50 of 0.075 μM	25352124
DLD-1	25 μM	Kinase Assay	48 h	Inhibition of JAK1 phosphorylation	24050550
DLD-1	25 μM	Kinase Assay	48 h	Inhibition of JAK2 phosphorylation	24050550
DLD-1	50 μM	Growth Inhibition Assay	48 h	IC50=15.51 μM	24050550
DLD-1	25 μM	Apoptosis Assay	48 h	Induces apoptosis by activating caspase 3	24050550
HEL	5 μM	Cytotoxic Assay	48 h	Cytotoxic index=12.2%	25931349
Hep3B	1 μM	Function Assay	16 h	Impaires the capacity of IHCA-associated gp130 mutants to active STAT3 with IC50 of ~50 μM	24501689
HepG2	1 μM	Function Assay	16 h	Impaires the capacity of IHCA-associated gp130 mutants to signal to STAT3	24501689
HT93A	320 nM	Growth Inhibition Assay	5 d	Inhibition of GCS-F induced granulocytic differentiation	25805962
Huh7	1 μM	Function Assay	16 h	Impaires the capacity of IHCA-associated gp130 mutants to signal to STAT3	24501689
HuH7	50 μM	Growth Inhibition Assay	48 h	>82% reduction	23941832
HuH7	50 μM	Function Assay	24 h	Inhibition of STAT1 and STAT3 phosphorylation significantly	23941832
Human monocyte		Kinase Assay		Inhibition of JAK2 in human monocytes expressing CD14 assessed as inhibition of GM-CSF-stimulated STAT5a phosphorylation with IC50 of 0.026μM	23540648
Human monocyte		Kinase Assay		Inhibition of JAK2/1 in human monocytes expressing CD14 assessed as inhibition of IFNgamma-stimulated STAT1 phosphorylation with IC50 of 0.031μM	23540648
Human T cell		Kinase Assay		Inhibition of JAK3/1 in human T cells expressing CD3 assessed as inhibition of IL2-stimulated STAT5a phosphorylation with IC50 of 0.023μM	23540648
NCI-H1299		Growth Inhibition Assay		IC50=0.28 μM	25213670
NCI-H1299	30 nM	Function Assay	48 h	Down-regulation of STAT3 phosphorylation	25213670
NCI-H1299	30 nM	Apoptosis Assay	48 h	Induction of apoptosis	25213670
NCI-H2347		Growth Inhibition Assay		IC50=0.17 μM	25213670
NCI-H2347	30 nM	Function Assay	48 h	Decrease in Bcl2 expression	25213670
NCI-H2347	30 nM	Apoptosis Assay	48 h	Induction of apoptosis	25213670
NCI-H358		Growth Inhibition Assay		IC50=0.1 μM	25213670
NCI-H460		Growth Inhibition Assay		IC50=0.13 μM	25213670
RKO	25 μM	Kinase Assay	48 h	Inhibition of JAK1 phosphorylation	24050550
RKO	25 μM	Kinase Assay	48 h	does not inhibit JAK1 phosphorylation	24050550
RKO	50 μM	Growth Inhibition Assay	48 h	IC50=14.76 μM	24050550
RKO	25 μM	Apoptosis Assay	48 h	Induces apoptosis by activating caspase 3	24050550
SET-2	5 μM	Cytotoxic Assay	48 h	Cytotoxic index=18.7%	25931349
SNU182	50 μM	Growth Inhibition Assay	48 h	>64% reduction	23941832
SNU182	50 μM	Function Assay	24 h	Inhibition of STAT1 and STAT3 phosphorylation significantly	23941832
SNU423	50 μM	Growth Inhibition Assay	48 h	>81% reduction	23941832
SNU423	50 μM	Function Assay	24 h	Inhibition of STAT1 and STAT3 phosphorylation significantly	23941832
TF1		Kinase Assay	20 min	Inhibition of JAK2 in human TF1 cells assessed as inhibition of EPO-induced STAT5 phosphorylation with IC50 of 0.012μM	22698084
TF1		Kinase Assay	20 min	Inhibition of JAK1 in human TF1 cells assessed as inhibition of IL6-induced STAT3 phosphorylation with IC50 of 0.024μM	22698084

芦可替尼 /Ruxolitinib 98%

Ruxolitinib 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Ruxolitinib 质控信息

Ruxolitinib 生物活性

Ruxolitinib 细胞研究

Ruxolitinib 动物研究

Ruxolitinib 临床研究

Ruxolitinib 参考文献

Ruxolitinib 实验方案

Ruxolitinib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

芦可替尼 /Ruxolitinib 98%

Ruxolitinib 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Ruxolitinib 质控信息

Ruxolitinib 生物活性

Ruxolitinib 细胞研究

Ruxolitinib 动物研究

Ruxolitinib 临床研究

Ruxolitinib 参考文献

Ruxolitinib 实验方案

Ruxolitinib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Ruxolitinib 纯度/质量文件产品仅供科研